Is treatment with trimetazidine beneficial in patients with chronic heart failure?

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Zhou, Xiang ^a   Chen, Jianchang ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; PLACEBO; TRIMETAZIDINE; VASODILATOR AGENT;

ARTICLE; DISEASE ASSOCIATION; EXERCISE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK RATIO; WEIGHTED MEAN DIFFERENCE; BLOOD; CHRONIC DISEASE; DRUG EFFECTS; FEMALE; HEART STROKE VOLUME; MALE; MEDLINE; METABOLISM; PATHOPHYSIOLOGY;

C-REACTIVE PROTEIN; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PUBMED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84900435758     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094660     Document Type: Article

References (29)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123: e18-e209.
2. Krum H, Teerlink JR (2011) Medical therapy for chronic heart failure. Lancet 378: 713-721.
3. Dedkova EN, Seidlmayer LK, Blatter LA (2013) Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure. J Mol Cell Cardiol 59: 41-54.
4. Ruixing Y, Wenwu L, Al-Ghazali R (2007) Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Transl Res 149: 152-160. (Pubitemid 46275573)
5. Zhou X, Li C, Xu W, Chen J (2012) Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PLoS One 7: e40424.
6. Belardinelli R, Solenghi M, Volpe L, Purcaro A (2007) Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J 28: 1102-1108. (Pubitemid 47343882)
7. Gao D, Ning N, Niu X, Hao G, Meng Z (2011) Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 97: 278-286.
8. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, et al. (2012) Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol 59: 913-922.
9. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. (Pubitemid 26120810)
10. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, et al. (1990) Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 11: 207-212. (Pubitemid 20119783)
11. Belardinelli R, Purcaro A (2001) Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 22: 2164-2170. (Pubitemid 33139462)
12. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, et al. (2003) Shortand long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 146: E18.
13. Rosano GMC, Vitale C, Sposato B, Mercuro G, Fini M (2003) Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: A double-blind placebo-controlled study. Cardiovasc Diabetol 2: 16.
14. Thrainsdottir IS, von Bibra H, Malmberg K, Ryden L (2004) Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 44: 101-108. (Pubitemid 38857135)
15. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, et al. (2004) Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25: 1814-1821. (Pubitemid 39330232)
16. El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S (2005) Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 5: 271-278. (Pubitemid 40994269)
17. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, et al. (2006) A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 48: 992-998. (Pubitemid 44292461)
18. Fragasso G, Perseghin G, Cobelli F, Esposito A, Palloshi A, et al. (2006) Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27: 942-948.
19. Di Napoli P, Taccardi AA, Barsotti A (2005) Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 91: 161-165.
20. Di Napoli P, Di Giovanni P, Gaeta MA, D'Apolito G, Barsotti A (2007) Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J 154: 602.e1-5.
21. Sisakian H, Torgomyan A, Barkhudaryan A (2007) The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy. Acta Cardiol 62: 493-499. (Pubitemid 47582642)
22. Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F (2008) Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol 51: 611-615.
23. Tuunanen H, Engblom E, Naum A, Nagren K, Scheinin M, et al. (2008) Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118: 1250-1258.
24. Gunes Y, Guntekin U, Tuncer M, Sahin M (2009) Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 24: 277-282.
25. Marazzi G, Gebara O, Vitale C, Caminiti G, Wajngarten M, et al. (2009) Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. Adv Ther 26: 455-461.
26. Cera M, Salerno A, Fragasso G, Montanaro C, Gardini C, et al. (2010) Beneficial electrophysiological effects of trimetazidine in patients with postischemic chronic heart failure. J Cardiovasc Pharmacol Ther 15: 24-30.
27. Fragasso G, Salerno A, Lattuada G, Cuko A, Calori G, et al. (2011) Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart 97: 1495-1500.
28. Zhao P, Zhang J, Yin XG, Maharaj P, Narraindoo S, et al. (2013) The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci 92: 633-638.
29. Kantor PF, Lucien A, Kozak R, Lopaschuk GD (2000) The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase. Circ Res 86: 580-588. (Pubitemid 30165050)